Tirzepatide has emerged as a groundbreaking treatment for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its availability have become key issues for patients and healthcare providers. While tirzepatide has been cleared by regulatory agencies, its costly nature presents a significant barrier to many.